A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-02

AUTHORS

Robin L. Jones, Stefano Ferrari, Jean Yves Blay, Fariba Navid, Pilar Lardelli, Vicente Alfaro, Mariano Siguero, Neelesh Soman, Sant P. Chawla

ABSTRACT

Ewing sarcoma is a rare connective tissue tumor characterized by the translocation of the EWS gene, mainly between chromosome 11 and 22, giving rise to gene re-arrangements between the EWS gene and various members of the ETS gene family. Multi-agent chemotherapy has improved the outcome for patients with localized Ewing sarcoma, but survival of patients with recurrent/metastatic disease remains poor. An exploratory two-stage, single-arm Phase II multicenter trial of the synthetic alkaloid, PM00104, was conducted in patients with recurrent Ewing sarcoma. The primary end point of the trial was objective response rate. PM00104 was administered at a dose of 2 mg/m(2) on Days 1, 8 and 15 of a 4 week cycle. Seventeen patients were recruited. No objective responses were reported in the 16 patients evaluable for efficacy. Recruitment was closed without proceeding to the second stage of the trial. Four patients achieved stable disease as best response, and in two of these patients the stabilization was longer than 4 months. The median progression-free survival was 1.8 months (95 % CI, 0.9-3.5 months) and median overall survival was not reached (95%CI, 56.2 % at censored data). Pharmacokinetics in patients with Ewing sarcoma was similar to that previously reported in other patient populations. PM00104 showed modest activity in Ewing sarcoma at 2 mg/m(2) on a weekly schedule. There remains an unmet need for effective therapies for patients with advanced/metastatic Ewing sarcoma. More... »

PAGES

171-177

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-013-0037-6

DOI

http://dx.doi.org/10.1007/s10637-013-0037-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042357544

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24173965


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma, Ewing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrahydroisoquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Fred Hutchinson Cancer Research Center", 
          "id": "https://www.grid.ac/institutes/grid.270240.3", 
          "name": [
            "University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Robin L.", 
        "id": "sg:person.01110361365.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Instituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrari", 
        "givenName": "Stefano", 
        "id": "sg:person.013005321532.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centre L\u00e9on B\u00e9rad, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blay", 
        "givenName": "Jean Yves", 
        "id": "sg:person.01336605441.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336605441.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St. Jude Children's Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.240871.8", 
          "name": [
            "Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Navid", 
        "givenName": "Fariba", 
        "id": "sg:person.01147112602.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147112602.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Zeltia (Spain)", 
          "id": "https://www.grid.ac/institutes/grid.425446.5", 
          "name": [
            "PharmaMar S.A., Colmenar Viejo, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lardelli", 
        "givenName": "Pilar", 
        "id": "sg:person.01171703441.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171703441.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Zeltia (Spain)", 
          "id": "https://www.grid.ac/institutes/grid.425446.5", 
          "name": [
            "PharmaMar S.A., Colmenar Viejo, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alfaro", 
        "givenName": "Vicente", 
        "id": "sg:person.01356104727.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356104727.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Zeltia (Spain)", 
          "id": "https://www.grid.ac/institutes/grid.425446.5", 
          "name": [
            "PharmaMar S.A., Colmenar Viejo, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Siguero", 
        "givenName": "Mariano", 
        "id": "sg:person.0632500627.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632500627.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sarcoma Oncology Center", 
          "id": "https://www.grid.ac/institutes/grid.477838.7", 
          "name": [
            "Sarcoma Oncology Center, Santa Monica, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soman", 
        "givenName": "Neelesh", 
        "id": "sg:person.01250627016.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250627016.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sarcoma Oncology Center", 
          "id": "https://www.grid.ac/institutes/grid.477838.7", 
          "name": [
            "Sarcoma Oncology Center, Santa Monica, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chawla", 
        "givenName": "Sant P.", 
        "id": "sg:person.0661314541.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661314541.57"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10637-012-9843-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002643899", 
          "https://doi.org/10.1007/s10637-012-9843-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-011-1644-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003635249", 
          "https://doi.org/10.1007/s00280-011-1644-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bcp.2009.04.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005396906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40272-013-0037-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005991337", 
          "https://doi.org/10.1007/s40272-013-0037-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/359162a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008302153", 
          "https://doi.org/10.1038/359162a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008312342", 
          "https://doi.org/10.1038/nature11005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng0294-146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012944240", 
          "https://doi.org/10.1038/ng0294-146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181dbebf9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018693800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181dbebf9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018693800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181dbebf9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018693800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pbc.21618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026831694"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737140.8.4.617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036207186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2008-09-177774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051998529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075329274", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-02", 
    "datePublishedReg": "2014-02-01", 
    "description": "Ewing sarcoma is a rare connective tissue tumor characterized by the translocation of the EWS gene, mainly between chromosome 11 and 22, giving rise to gene re-arrangements between the EWS gene and various members of the ETS gene family. Multi-agent chemotherapy has improved the outcome for patients with localized Ewing sarcoma, but survival of patients with recurrent/metastatic disease remains poor. An exploratory two-stage, single-arm Phase II multicenter trial of the synthetic alkaloid, PM00104, was conducted in patients with recurrent Ewing sarcoma. The primary end point of the trial was objective response rate. PM00104 was administered at a dose of 2 mg/m(2) on Days 1, 8 and 15 of a 4 week cycle. Seventeen patients were recruited. No objective responses were reported in the 16 patients evaluable for efficacy. Recruitment was closed without proceeding to the second stage of the trial. Four patients achieved stable disease as best response, and in two of these patients the stabilization was longer than 4 months. The median progression-free survival was 1.8 months (95 % CI, 0.9-3.5 months) and median overall survival was not reached (95%CI, 56.2 % at censored data). Pharmacokinetics in patients with Ewing sarcoma was similar to that previously reported in other patient populations. PM00104 showed modest activity in Ewing sarcoma at 2 mg/m(2) on a weekly schedule. There remains an unmet need for effective therapies for patients with advanced/metastatic Ewing sarcoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-013-0037-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "name": "A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors", 
    "pagination": "171-177", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c9c487c5b8c78855cdca98f506dd6d3ff576cb554111fdcd7f3e1f80062b287c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24173965"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-013-0037-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042357544"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-013-0037-6", 
      "https://app.dimensions.ai/details/publication/pub.1042357544"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000515.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-013-0037-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0037-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0037-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0037-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0037-6'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      55 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-013-0037-6 schema:about N1e77527a58fe415db339bcf3a4f04a09
2 N212d47541d0f45b19bdac41d69c6e121
3 N4821a184cfcb47298c087a8f75f6b714
4 N50121dd26df544df8947ce7d6dcfda71
5 N5928b7216aa146c2981455d7d550562a
6 N8f30dec91fbe461cb26ac41d87c2797d
7 Na057d0ecd2f041dc9ed40b41222cf170
8 Na2630a8ad7ac488ea0078ee0b3a2d0a7
9 Nc018186afd354ef29c7f0d58265dae6a
10 Nc63102039d0a40cf971db1c5e879afce
11 Ne612774830c04ca3a52cd679151a0bfd
12 Nfa22b600f6944cedb6619fc94a15677c
13 Nfdcab1a0022e4131be1c1a5d3041e2d6
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N4833ae144e05412fa5fea71db9070e06
17 schema:citation sg:pub.10.1007/s00280-011-1644-6
18 sg:pub.10.1007/s10637-012-9843-5
19 sg:pub.10.1007/s40272-013-0037-1
20 sg:pub.10.1038/359162a0
21 sg:pub.10.1038/nature11005
22 sg:pub.10.1038/ng0294-146
23 https://app.dimensions.ai/details/publication/pub.1075329274
24 https://doi.org/10.1002/pbc.21618
25 https://doi.org/10.1016/j.bcp.2009.04.003
26 https://doi.org/10.1016/j.ejca.2008.10.026
27 https://doi.org/10.1097/ppo.0b013e3181dbebf9
28 https://doi.org/10.1182/blood-2008-09-177774
29 https://doi.org/10.1586/14737140.8.4.617
30 schema:datePublished 2014-02
31 schema:datePublishedReg 2014-02-01
32 schema:description Ewing sarcoma is a rare connective tissue tumor characterized by the translocation of the EWS gene, mainly between chromosome 11 and 22, giving rise to gene re-arrangements between the EWS gene and various members of the ETS gene family. Multi-agent chemotherapy has improved the outcome for patients with localized Ewing sarcoma, but survival of patients with recurrent/metastatic disease remains poor. An exploratory two-stage, single-arm Phase II multicenter trial of the synthetic alkaloid, PM00104, was conducted in patients with recurrent Ewing sarcoma. The primary end point of the trial was objective response rate. PM00104 was administered at a dose of 2 mg/m(2) on Days 1, 8 and 15 of a 4 week cycle. Seventeen patients were recruited. No objective responses were reported in the 16 patients evaluable for efficacy. Recruitment was closed without proceeding to the second stage of the trial. Four patients achieved stable disease as best response, and in two of these patients the stabilization was longer than 4 months. The median progression-free survival was 1.8 months (95 % CI, 0.9-3.5 months) and median overall survival was not reached (95%CI, 56.2 % at censored data). Pharmacokinetics in patients with Ewing sarcoma was similar to that previously reported in other patient populations. PM00104 showed modest activity in Ewing sarcoma at 2 mg/m(2) on a weekly schedule. There remains an unmet need for effective therapies for patients with advanced/metastatic Ewing sarcoma.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N1f643f49a6f84708a5629a71f2f7c057
37 N60ed9236254a4cc689cc748c7605b736
38 sg:journal.1094201
39 schema:name A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors
40 schema:pagination 171-177
41 schema:productId N45eb8b9f0f5b4508ab30814f427912a8
42 N8a0b9436e9f5420892482a7e46935ffa
43 Nbdbb6d1339784a2a8182460321aab17f
44 Nd8ae9ba0d5e147bab8a32b1bfe8fe579
45 Nf1caf4bf431f4695a08c86ca7a0a4ecd
46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042357544
47 https://doi.org/10.1007/s10637-013-0037-6
48 schema:sdDatePublished 2019-04-10T19:09
49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
50 schema:sdPublisher Ne8c57ba656ff4413a32132b0a990e430
51 schema:url http://link.springer.com/10.1007%2Fs10637-013-0037-6
52 sgo:license sg:explorer/license/
53 sgo:sdDataset articles
54 rdf:type schema:ScholarlyArticle
55 N0a71c8be92c44be48f4eb37cb60a79eb rdf:first sg:person.01356104727.37
56 rdf:rest N3c86f23733ee4bc7a694743ff47e63fe
57 N0bfe44d3286d4f8b8367e7d0976e7595 rdf:first sg:person.0661314541.57
58 rdf:rest rdf:nil
59 N1e77527a58fe415db339bcf3a4f04a09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Young Adult
61 rdf:type schema:DefinedTerm
62 N1f643f49a6f84708a5629a71f2f7c057 schema:volumeNumber 32
63 rdf:type schema:PublicationVolume
64 N212d47541d0f45b19bdac41d69c6e121 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Humans
66 rdf:type schema:DefinedTerm
67 N24b4ae1ca5434a6fbaee934aee97fd32 rdf:first sg:person.01336605441.13
68 rdf:rest Nca8c4a27e73145ddb7b9129b74d2b8be
69 N3c7d59d866a74e1789d4b5c9f0e85422 rdf:first sg:person.01250627016.58
70 rdf:rest N0bfe44d3286d4f8b8367e7d0976e7595
71 N3c86f23733ee4bc7a694743ff47e63fe rdf:first sg:person.0632500627.48
72 rdf:rest N3c7d59d866a74e1789d4b5c9f0e85422
73 N45eb8b9f0f5b4508ab30814f427912a8 schema:name pubmed_id
74 schema:value 24173965
75 rdf:type schema:PropertyValue
76 N4821a184cfcb47298c087a8f75f6b714 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Adult
78 rdf:type schema:DefinedTerm
79 N4833ae144e05412fa5fea71db9070e06 rdf:first sg:person.01110361365.31
80 rdf:rest Nf04a0af4afe84c35bd495d8da437ab9c
81 N50121dd26df544df8947ce7d6dcfda71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Tetrahydroisoquinolines
83 rdf:type schema:DefinedTerm
84 N5928b7216aa146c2981455d7d550562a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Female
86 rdf:type schema:DefinedTerm
87 N60ed9236254a4cc689cc748c7605b736 schema:issueNumber 1
88 rdf:type schema:PublicationIssue
89 N8a0b9436e9f5420892482a7e46935ffa schema:name dimensions_id
90 schema:value pub.1042357544
91 rdf:type schema:PropertyValue
92 N8f30dec91fbe461cb26ac41d87c2797d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Antineoplastic Agents
94 rdf:type schema:DefinedTerm
95 Na057d0ecd2f041dc9ed40b41222cf170 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Area Under Curve
97 rdf:type schema:DefinedTerm
98 Na2630a8ad7ac488ea0078ee0b3a2d0a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Treatment Outcome
100 rdf:type schema:DefinedTerm
101 Nb3872eb6e0cd41d59ea6cbd4c3bc17d2 rdf:first sg:person.01171703441.01
102 rdf:rest N0a71c8be92c44be48f4eb37cb60a79eb
103 Nbbafcf390e3f4cb1b495cc4af77a1184 schema:name Instituto Ortopedico Rizzoli, Bologna, Italy
104 rdf:type schema:Organization
105 Nbdbb6d1339784a2a8182460321aab17f schema:name nlm_unique_id
106 schema:value 8309330
107 rdf:type schema:PropertyValue
108 Nc018186afd354ef29c7f0d58265dae6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Male
110 rdf:type schema:DefinedTerm
111 Nc63102039d0a40cf971db1c5e879afce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Sarcoma, Ewing
113 rdf:type schema:DefinedTerm
114 Nca8c4a27e73145ddb7b9129b74d2b8be rdf:first sg:person.01147112602.50
115 rdf:rest Nb3872eb6e0cd41d59ea6cbd4c3bc17d2
116 Nd8ae9ba0d5e147bab8a32b1bfe8fe579 schema:name readcube_id
117 schema:value c9c487c5b8c78855cdca98f506dd6d3ff576cb554111fdcd7f3e1f80062b287c
118 rdf:type schema:PropertyValue
119 Ne612774830c04ca3a52cd679151a0bfd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Neoplasm Staging
121 rdf:type schema:DefinedTerm
122 Ne8c57ba656ff4413a32132b0a990e430 schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 Nf04a0af4afe84c35bd495d8da437ab9c rdf:first sg:person.013005321532.44
125 rdf:rest N24b4ae1ca5434a6fbaee934aee97fd32
126 Nf1caf4bf431f4695a08c86ca7a0a4ecd schema:name doi
127 schema:value 10.1007/s10637-013-0037-6
128 rdf:type schema:PropertyValue
129 Nf741786a7acd42bbb63eed99dfe1abca schema:name Centre Léon Bérad, Lyon, France
130 rdf:type schema:Organization
131 Nfa22b600f6944cedb6619fc94a15677c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Adolescent
133 rdf:type schema:DefinedTerm
134 Nfdcab1a0022e4131be1c1a5d3041e2d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Middle Aged
136 rdf:type schema:DefinedTerm
137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
138 schema:name Medical and Health Sciences
139 rdf:type schema:DefinedTerm
140 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
141 schema:name Oncology and Carcinogenesis
142 rdf:type schema:DefinedTerm
143 sg:journal.1094201 schema:issn 0167-6997
144 1573-0646
145 schema:name Investigational New Drugs
146 rdf:type schema:Periodical
147 sg:person.01110361365.31 schema:affiliation https://www.grid.ac/institutes/grid.270240.3
148 schema:familyName Jones
149 schema:givenName Robin L.
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31
151 rdf:type schema:Person
152 sg:person.01147112602.50 schema:affiliation https://www.grid.ac/institutes/grid.240871.8
153 schema:familyName Navid
154 schema:givenName Fariba
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147112602.50
156 rdf:type schema:Person
157 sg:person.01171703441.01 schema:affiliation https://www.grid.ac/institutes/grid.425446.5
158 schema:familyName Lardelli
159 schema:givenName Pilar
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171703441.01
161 rdf:type schema:Person
162 sg:person.01250627016.58 schema:affiliation https://www.grid.ac/institutes/grid.477838.7
163 schema:familyName Soman
164 schema:givenName Neelesh
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250627016.58
166 rdf:type schema:Person
167 sg:person.013005321532.44 schema:affiliation Nbbafcf390e3f4cb1b495cc4af77a1184
168 schema:familyName Ferrari
169 schema:givenName Stefano
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44
171 rdf:type schema:Person
172 sg:person.01336605441.13 schema:affiliation Nf741786a7acd42bbb63eed99dfe1abca
173 schema:familyName Blay
174 schema:givenName Jean Yves
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336605441.13
176 rdf:type schema:Person
177 sg:person.01356104727.37 schema:affiliation https://www.grid.ac/institutes/grid.425446.5
178 schema:familyName Alfaro
179 schema:givenName Vicente
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356104727.37
181 rdf:type schema:Person
182 sg:person.0632500627.48 schema:affiliation https://www.grid.ac/institutes/grid.425446.5
183 schema:familyName Siguero
184 schema:givenName Mariano
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632500627.48
186 rdf:type schema:Person
187 sg:person.0661314541.57 schema:affiliation https://www.grid.ac/institutes/grid.477838.7
188 schema:familyName Chawla
189 schema:givenName Sant P.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661314541.57
191 rdf:type schema:Person
192 sg:pub.10.1007/s00280-011-1644-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003635249
193 https://doi.org/10.1007/s00280-011-1644-6
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/s10637-012-9843-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002643899
196 https://doi.org/10.1007/s10637-012-9843-5
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/s40272-013-0037-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005991337
199 https://doi.org/10.1007/s40272-013-0037-1
200 rdf:type schema:CreativeWork
201 sg:pub.10.1038/359162a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008302153
202 https://doi.org/10.1038/359162a0
203 rdf:type schema:CreativeWork
204 sg:pub.10.1038/nature11005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008312342
205 https://doi.org/10.1038/nature11005
206 rdf:type schema:CreativeWork
207 sg:pub.10.1038/ng0294-146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012944240
208 https://doi.org/10.1038/ng0294-146
209 rdf:type schema:CreativeWork
210 https://app.dimensions.ai/details/publication/pub.1075329274 schema:CreativeWork
211 https://doi.org/10.1002/pbc.21618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026831694
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/j.bcp.2009.04.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005396906
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1097/ppo.0b013e3181dbebf9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018693800
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1182/blood-2008-09-177774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051998529
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1586/14737140.8.4.617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036207186
222 rdf:type schema:CreativeWork
223 https://www.grid.ac/institutes/grid.240871.8 schema:alternateName St. Jude Children's Research Hospital
224 schema:name Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA
225 rdf:type schema:Organization
226 https://www.grid.ac/institutes/grid.270240.3 schema:alternateName Fred Hutchinson Cancer Research Center
227 schema:name University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA
228 rdf:type schema:Organization
229 https://www.grid.ac/institutes/grid.425446.5 schema:alternateName Zeltia (Spain)
230 schema:name PharmaMar S.A., Colmenar Viejo, Madrid, Spain
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.477838.7 schema:alternateName Sarcoma Oncology Center
233 schema:name Sarcoma Oncology Center, Santa Monica, CA, USA
234 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...